A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions

Lymphoid Malignancies

Interventions

DRUG

GS-9820

GS-9820 tablets containing 200 mg of GS-9820 administered orally

Trial Locations (4)

VU Medical Center (VUmc), Amsterdam

Academic Medical Center, Amsterdam

St. Antonius Hospital, Nieuwegein

Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam